Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.48 5.53% 0.13
ACRX closed up 5.53 percent on Thursday, January 17, 2019, on 77 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ACRX trend table...

Date Alert Name Type % Chg
Jan 17 Crossed Above 20 DMA Bullish 0.00%
Jan 17 Pocket Pivot Bullish Swing Setup 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Doji - Bullish? Reversal 5.53%
Jan 16 Wide Bands Range Expansion 5.53%
Jan 15 Wide Bands Range Expansion 5.53%
Jan 15 Down 3 Days in a Row Weakness 5.53%
Jan 15 Down 4 Days in a Row Weakness 5.53%
Jan 14 Fell Below 20 DMA Bearish 1.64%
Jan 14 Wide Bands Range Expansion 1.64%

Older signals for ACRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.05
52 Week Low 1.65
Average Volume 2,678,610
200-Day Moving Average 3.1452
50-Day Moving Average 2.9522
20-Day Moving Average 2.463
10-Day Moving Average 2.601
Average True Range 0.2316
ADX 16.19
+DI 18.31
-DI 24.8781
Chandelier Exit (Long, 3 ATRs ) 2.2252
Chandelier Exit (Short, 3 ATRs ) 2.6848
Upper Bollinger Band 2.881
Lower Bollinger Band 2.045
Percent B (%b) 0.52
BandWidth 33.942347
MACD Line -0.1262
MACD Signal Line -0.1446
MACD Histogram 0.0184
Fundamentals Value
Market Cap 112.54 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -2.25
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.86
Resistance 3 (R3) 2.84 2.68 2.80
Resistance 2 (R2) 2.68 2.58 2.69 2.78
Resistance 1 (R1) 2.58 2.52 2.63 2.61 2.76
Pivot Point 2.43 2.43 2.45 2.44 2.43
Support 1 (S1) 2.33 2.33 2.38 2.35 2.20
Support 2 (S2) 2.17 2.27 2.18 2.18
Support 3 (S3) 2.07 2.17 2.16
Support 4 (S4) 2.10